Trial Profile
A clinical trial of NT-3 gene therapy for Charcot-Marie-Tooth (CMT) type 1A
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs Gene therapies (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Adverse reactions
- 12 Oct 2018 New trial record
- 05 Oct 2018 According to a Sarepta Therapeutics media release, the study is scheduled to initiate in 2019.